相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Free iron catalyzes oxidative damage to hematopoietic cells/mesenchymal stem cells in vitro and suppresses hematopoiesis in iron overload patients
Wenyi Lu et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2013)
Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes
Julia Hartmann et al.
LEUKEMIA RESEARCH (2013)
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes
Norbert Gattermann et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion-Dependent Patients With Myelodysplastic Syndrome
Alan F. List et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Improved survival in MDS patients receiving iron chelation therapy - A matched pair analysis of 188 patients from the Dusseldorf MDS registry
Judith Neukirchen et al.
LEUKEMIA RESEARCH (2012)
Deferasirox is a powerful NF-κB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging
Emanuela Messa et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM
Christian Rose et al.
LEUKEMIA RESEARCH (2010)
Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients
Esther Natalie Oliva et al.
TRANSFUSION (2010)
The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1
Junko H. Ohyashiki et al.
CANCER SCIENCE (2009)
Iron injections in mice increase skeletal muscle iron content, induce oxidative stress and reduce exercise performance
Trent F. Reardon et al.
EXPERIMENTAL PHYSIOLOGY (2009)
Deferasirox Treatment Improved the Hemoglobin Level and Decreased Transfusion Requirements in Four Patients with the Myelodysplastic Syndrome and Primary Myelofibrosis
E. Messa et al.
ACTA HAEMATOLOGICA (2008)
Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells
Hong Qian et al.
CELL STEM CELL (2007)
Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade®, ICL670)
Anna Angela Di Tucci et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2007)
Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches
Tatsuki Sugiyama et al.
IMMUNITY (2006)
Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells
K Ito et al.
NATURE MEDICINE (2006)
Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders
C Camaschella
BLOOD (2005)
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making
L Malcovati et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes
R Tehranchi et al.
BLOOD (2005)
Flow cytometric analysis of the oxidative status of normal and thalassemic red blood cells
J Amer et al.
CYTOMETRY PART A (2004)
Chemistry and biology of eukaryotic iron metabolism
P Aisen et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2001)
分享论文
